SCHEMBL4048641

SCHEMBL4048641

C#CC(OC)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.46
ACHE P22303 1/20 0.43
MAPT P10636 4/20 0.42
CYP3A4 P08684 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
TUBB4A P04350 3/20 0.40
TUBB P07437 3/20 0.40
TUBA3C P0DPH7 3/20 0.40
TUBA1B P68363 3/20 0.40
TUBA4A P68366 3/20 0.40
TUBB4B P68371 3/20 0.40
TUBB3 Q13509 3/20 0.40
TUBB2A Q13885 3/20 0.40
TUBB8 Q3ZCM7 3/20 0.40
TUBA3E Q6PEY2 3/20 0.40
TUBA1A Q71U36 3/20 0.40
TUBA1C Q9BQE3 3/20 0.40
TUBB6 Q9BUF5 3/20 0.40
TUBB2B Q9BVA1 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4044841 0.78 ACHE (0.45) DHFRACHEMAPTCYP3A4CA9
SCHEMBL4036492 0.78 ACHE (0.45) DHFRACHEMAPTCYP3A4CA9
SCHEMBL3953279 0.78 ACHE (0.45) DHFRACHEMAPTCYP3A4CA9
SCHEMBL3952609 0.77 TUBB4A (0.47) DHFRACHEMAPTCYP3A4CA9
SCHEMBL9135690 0.73 ACHE (0.52) ACHEMAPTCYP3A4CA9L3MBTL1
SCHEMBL11951323 0.71 ACHE (0.50) ACHEMAPTCYP3A4CA9L3MBTL1
SCHEMBL11951324 0.71 ACHE (0.50) ACHEMAPTCYP3A4CA9L3MBTL1
SCHEMBL683553 0.70 ACHE (0.54) ACHEMAPTCYP3A4CA9L3MBTL1
SCHEMBL9828544 0.70 ACHE (0.54) ACHEMAPTCYP3A4CA9L3MBTL1
SCHEMBL14962848 0.69 MAPT (0.52) ACHEMAPTCYP3A4CA9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776404-B1 HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE UNIV CONNECTICUT (US) 2016-07-06 EP disclosed
US-8853228-B2 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase UNIVERSITY OF CONNECTICUT (US) 2014-10-07 US disclosed
EP-2776404-A1 HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE University of Connecticut (US) 2014-09-17 EP disclosed
WO-2013070620-A1 HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE UNIVERSITY OF CONNECTICUT (US) 2013-05-16 WO disclosed
US-8426432-B2 Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties UNIVERSITY OF CONNECTICUT (US) 2013-04-23 US disclosed
US-20120196859-A1 HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE UNIVERSITY OF CONNECTICUT 2012-08-02 US disclosed
US-20090105287-A1 Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties UNIVERSITY OF CONNECTICUT (US) 2009-04-23 US disclosed
WO-2009025919-A2 5-PROPARGYL-PYRIMIDINE DERIVATIVES AS INHIBITORS OF DIHYDROFOLATE REDUCTASE WITH ANTIBACTERIAL ANTIPROTOZOAL, ANTIFUNGAL AND ANTICANCER PROPERTIES UNIVERSITY OF CONNECTICUT (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105287-A1 Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties DHFR, DPYD, DHODH DHFR 1/4885ACHE 3284/4885MAPT 3672/4885
US-20120196859-A1 HETEROCYCLIC ANALOGS OF PROPARGYL-LINKED INHIBITORS OF DIHYDROFOLATE REDUCTASE DHFR, DPYD, DHODH DHFR 1/4885ACHE 3385/4885MAPT 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.